Cryopreservation

Key Facts

• Entity type: Laboratory and clinical preservation method for biological material.
• Definition: Cooling and storing cells, tissues or organs at very low or freezing temperatures to save them for future use [1].
• Typical storage medium: Liquid nitrogen (vapour or liquid phase), commonly cited at approximately −196 °C, with cryoprotective agents added before freezing. source pending
• Effect on adipose stromal vascular fraction (SVF): A 2019 study reported that cryopreservation reduces SVF cell counts but not the stem cell potency of the surviving cells [4].
• Evidence synthesis: A 2026 systematic review examined the effects of cryopreservation on SVF viability in human adipose tissue [5].
• Governance: Stem cell research and clinical translation, including cell handling, storage and consent, are addressed in international guidance such as the ISSCR Guidelines [2].
• Status of this page: Medical draft prepared for expert review; not medical advice.

Definition

Cryopreservation is the process of cooling and storing cells, tissues or organs at very low or freezing temperatures so that they can be saved for future use [1]. The aim is to arrest biological activity, including metabolism and degradation, so that the biological material can later be thawed and used with as much of its original structure and function as possible.

In the context of adipose-derived cell therapy and research, cryopreservation is most often applied to the stromal vascular fraction (SVF) — the heterogeneous cell population obtained from processed fat tissue — or to culture-expanded adipose-derived stromal/stem cells. Cryopreservation allows a single tissue harvest to be divided, banked and used over time rather than being processed and applied in a single session.

Medical and Scientific Background

Cells are largely composed of water. When biological material is cooled below freezing, extracellular ice forms first, which concentrates solutes outside the cell and draws water out of the cell by osmosis. Depending on the cooling rate, cells may be damaged by dehydration and osmotic stress (slow cooling) or by the formation of intracellular ice crystals that disrupt membranes and organelles (rapid cooling). Cryopreservation protocols therefore aim to balance these competing injury mechanisms. source pending

To reduce this damage, cryoprotective agents are added before freezing. These substances lower the amount of ice that forms and stabilise cell membranes during cooling and warming. Because cryoprotectants can themselves be toxic to cells at higher concentrations and temperatures, exposure time, concentration and temperature are controlled, and the agents are usually diluted or washed out after thawing. source pending

Below approximately −130 °C, water-based biological systems are generally considered to be in a glass-like (vitrified) or otherwise biologically inert state in which molecular movement is effectively halted; this is the rationale for long-term storage in liquid nitrogen or its vapour phase. source pending

How It Works

1. Collection and processing: The biological material is obtained (for SVF, by lipoaspiration and subsequent enzymatic or mechanical processing of adipose tissue) and assessed for cell yield and viability.
2. Addition of cryoprotectant: Cells are suspended in a freezing medium containing one or more cryoprotective agents, usually in combination with a carrier solution and/or protein source. source pending
3. Controlled cooling: The sample is cooled at a defined rate, often using a controlled-rate freezer or an insulated cooling device, to reach cryogenic temperatures in a reproducible way. source pending
4. Long-term storage: Vials or bags are transferred to liquid nitrogen storage (liquid or vapour phase) with temperature monitoring, alarms and inventory records.
5. Thawing and preparation: The sample is rapidly warmed, the cryoprotectant is diluted or removed, and post-thaw cell count, viability and (in research settings) functional assays are performed before use.

Post-thaw quality control is central: cell number, viability and functional capacity are the outcomes most commonly reported to describe whether a cryopreservation protocol was successful [4][5].

Applications

• Cell and tissue banking: Storing cells, tissues or organs so they remain available for future use [1].
• Adipose-derived cell workflows: Banking SVF or adipose-derived stromal cells so that material harvested once can be characterised, released and used in later sessions or experiments [4][5].
• Research and manufacturing logistics: Decoupling tissue collection from laboratory analysis, allowing batching, shipment and standardised testing.
• Quality assurance: Retaining reference or retention samples for later identity, sterility or potency testing.
• Clinical translation: Supporting the controlled, documented handling of cell products described in international stem cell research and translation guidance [2].

Potential Benefits

• Time flexibility: Cells can be preserved for future use rather than requiring immediate application [1].
• Fewer harvesting procedures: One tissue harvest may supply material for multiple planned uses, potentially reducing repeat interventions.
• Testing before use: Storage creates time for sterility, identity and potency testing, which supports quality control and traceability [2].
• Retained potency of surviving cells: In the reported 2019 SVF study, cryopreservation reduced cell counts but not the stem cell potency of the cells that survived [4].

Limitations

• Cell loss: Freezing and thawing reduce the number of recoverable, viable cells; this is a consistent theme in SVF research [4][5].
• Protocol heterogeneity: Cryoprotectant type and concentration, cooling rate, storage duration and thawing method vary between laboratories, which complicates comparison of results; a 2026 systematic review was undertaken to examine the effects of cryopreservation on SVF viability in human adipose tissue [5].
• Surrogate outcomes: Most available data describe laboratory endpoints such as viability, cell count and differentiation capacity rather than patient-level clinical outcomes after use of cryopreserved cells. source pending
• Infrastructure dependence: Continuous cryogenic storage requires equipment, monitoring, nitrogen supply and documented chain of custody; interruptions can compromise the stored material.
• Unproven clinical claims: Banking cells does not in itself establish that a later treatment will be effective; independent patient resources emphasise caution about stem cell interventions whose benefits have not been demonstrated in controlled studies [3].

Risks and Safety

• Reduced potency or viability on thaw: Sub-optimal protocols can leave too few viable cells for the intended purpose [4][5].
• Cryoprotectant exposure: Residual cryoprotective agents may be toxic to cells and, if infused, may cause reactions in recipients; dilution or washing steps are used to limit this. source pending
• Contamination: Microbial contamination can be introduced during harvesting, processing or thawing, and liquid-phase nitrogen storage carries a theoretical risk of cross-contamination between samples. source pending
• Storage failure and sample mix-up: Equipment failure, inadequate temperature monitoring or labelling errors can render material unusable or unsafe.
• Occupational hazards: Handling liquid nitrogen involves risks of cold burns and asphyxiation in poorly ventilated areas, requiring trained staff and protective equipment. source pending
• Procedure-related risks: Risks associated with the original tissue harvest (for SVF, liposuction) are separate from cryopreservation itself and should be discussed independently.

Who May or May Not Be Suitable

Suitability is determined by the intended use of the cells, the applicable national regulations and individual clinical assessment, not by cryopreservation as such.

May be considered

• People enrolled in a regulated clinical trial or an approved treatment pathway in which cells are collected at one time point and used later.
• Situations where laboratory release testing must be completed before administration [2].
• Research contexts where samples must be batched, shipped or analysed at a later date [5].

May not be suitable

• Individuals with active infection, or samples from tissue that cannot meet donor screening and sterility requirements, according to the applicable regulatory framework. source pending
• Contexts where the intended later use is an intervention without evidence of benefit; independent patient guidance advises careful scrutiny of unproven stem cell offers [3].
• Settings lacking validated protocols, temperature monitoring, documentation and informed consent processes [2].

Evidence

The concept of cryopreservation is well established and is defined by the National Cancer Institute as cooling and storing cells, tissues or organs at very low or freezing temperatures to save them for future use [1].

For adipose-derived material specifically, a 2019 study published in Plastic and Reconstructive Surgery – Global Open reported that cryopreservation of stromal vascular fraction cells reduces their counts but not their stem cell potency [4]. A 2026 systematic review in Tissue Engineering and Regenerative Medicine examined the effects of cryopreservation on SVF viability in human adipose tissue, consolidating findings across published protocols [5].

Quantitative pooled figures for post-thaw viability, recovery rates and storage duration effects are not reproduced here because they are not stated in the sources listed for this page. source pending

Framework documents from the International Society for Stem Cell Research address the standards expected in stem cell research and clinical translation, including oversight, documentation and consent [2], while its patient-facing resource explains what current evidence does and does not support for stem cell interventions [3].

Regulation, Documentation and Consent

Storage conditions, record-keeping and informed consent for banked human cells are regulated in most countries, and requirements differ by jurisdiction and by whether the material is used in research, in a clinical trial or as an authorised product. International guidance recommends transparent documentation, oversight of cell processing, and consent that accurately describes intended use and limitations [2]. Specific national rules, licence categories, permitted storage periods and fees are outside the scope of the sources cited here. source pending

Comparison

This page is not a direct "A versus B" comparison, so no head-to-head comparison section is provided. The practical alternative to cryopreservation is immediate (fresh) use of the processed cell population, which avoids freeze–thaw cell loss but removes the opportunity to complete release testing and to reuse material from a single harvest at a later date [4][5].